Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874116 · ClinicalTrials.gov registry record · NA
Decreasing Cardiovascular Risk for Patients With Diabetes
A NA study of Diabetes Mellitus, Type 2, sponsored by Michigan State University.
- Active
- Registry status
- NA
- Development phase
- 378
- Enrollment target
- 1
- Study location
NCT04874116 is a NA study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Michigan State University. The registered enrollment target is 378 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04874116, a NA study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Michigan State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 378 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiovascular disease (CVD) complications are the leading cause of diabetes mellitus (DM)-related morbidity and mortality, creating a significant burden on the public health system. This burden is, in part, attributable to poor medication adherence, with 21-42% of patients failing to properly adhere to their care. Importantly, this issue is especially pronounced in minority and low-income populations, which show higher rates of chronic illness and lower medication adherence. Interventions that foster and reinforce patient-centered communication between clinicians and patients show promise in improving health outcomes. However, they have not been widely implemented, in part due to a lack of compelling evidence for their effectiveness in primary care settings. Project Objective: The investigators propose to evaluate the impact of a patient activation program: Office Guidelines Applied to Practice (Office-GAP) combined with mobile text messaging reinforcement (Way to Health \[W2H\]) on medication adherence in patients with DM compared to mobile texting alone. Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. W2H is a texting service that informs and encourages patients to adhere to goals and improve communication. The long-term goal is to develop a model that can reliably improve and sustain adherence and can be successfully implemented in primary care clinics to close the morbidity and mortality gap for minority/low-income DM patients. The hypothesis is that the combined face-to-face patient activation and texting- delivered reinforcement methods will facilitate communication between patients and providers, improving the frequency, accuracy, and timeliness of communication while reinforcing shared goals and engendering mutual respect more than texting alone. Improved communication between patients and providers may improve medication adherence, blood
Conditions Studied
Interventions
- BEHAVIORAL Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging
- BEHAVIORAL Mobile text messaging
Study Locations (1)
Michigan
- Ingham Healthcare center - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04874116
The ClinicalTrials.gov registry entry for NCT04874116 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The listed sponsor is Michigan State University, which has 120 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging is the first listed.
NCT04874116 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04874116 about?
NCT04874116 is a clinical study titled "Decreasing Cardiovascular Risk for Patients With Diabetes". Cardiovascular disease (CVD) complications are the leading cause of diabetes mellitus (DM)-related morbidity and mortality, creating a significant burden on the public health system. This burden is, in part, attributable to poor medication adherence, with 21-42% of patients failing to properly adher...
What is the current status of trial NCT04874116?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 378 participants. The study started on 2021-05-26. Estimated completion is 2026-09-30.
What conditions does trial NCT04874116 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT04874116?
The interventions under investigation include: Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging (BEHAVIORAL), Mobile text messaging (BEHAVIORAL).
Who is sponsoring clinical trial NCT04874116?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04874116 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.